Recent advances have seen immuno-therapy become a shining light within oncology research, transforming both the way cancer treatments are viewed and the potential standards of care and outcomes.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh